Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News

This article was originally published in The Pink Sheet Daily

Executive Summary

Known for his thought-provoking views on transforming Indian pharmaceutical research, Barbhaiya says multinational companies should shed conventional methods when teaming up with Indian companies for true innovation to thrive.
Advertisement

Related Content

Advinus Bets On Novel Glucokinase, Claiming Advantages Over Peer Compounds As It Scans For Out-licensing Deal
Advinus Bets On Novel Glucokinase, Claiming Advantages Over Peer Compounds As It Scans For Out-licensing Deal
Merck's Chief Strategy Officer Mervyn Turner Talks To PharmAsia News About Partnerships And Transformational Research Models

Topics

Advertisement
UsernamePublicRestriction

Register

PS071206

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel